Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Chimeric |
Target | CLDN18.2 |
Clinical data | |
Other names | IMAB362; Claudiximab |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
(what is this?) (verify) |
Zolbetuximab (development code IMAB362) is an experimental monoclonal antibody against isoform 2 of Claudin-18. It is under investigation for the treatment of gastrointestinal adenocarcinomas and pancreatic tumors. IMAB362 was developed by Ganymed Pharmaceuticals AG.[1] Astellas Pharmaceuticals acquired the rights to Zolbetuximab in December, 2016 when it acquired Ganymed Pharmaceuticals. [2]
The drug was in phase III clinical trials as of November 2021[update] for gastric cancer.[3][4][5][6]